Perrigo Company PLC - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Perrigo Company PLC and Perrigo Finance PLC on November 24, 2014. The filing details significant corporate finance events, including the release of existing guarantees, the full exercise of an equity offering greenshoe option, and the commencement of a new senior notes offering to fund a proposed acquisition.
Key Financial Metrics and Transactions
- Equity Offering: Underwriters exercised their option in full to purchase an additional 888,157 ordinary shares at $152.00 per share (less underwriting discount).
- Debt Offering: Perrigo Finance plc commenced a registered public offering of three series of Senior Notes ("New Notes").
- Guarantees: Guarantors under the November 8, 2013 Indenture were released of their obligations as of November 21, 2014.
- Use of Proceeds: Net proceeds from the New Notes are intended to fund a portion of the cash consideration for the proposed acquisition of Omega Pharma Invest NV.
Material Changes and Strategic Actions
The filing reports the launch of a new debt offering specifically tied to the Omega Pharma acquisition strategy. While the offering is not contingent on the acquisition's success, the company has outlined a contingency plan: if the acquisition is not consummated, proceeds will be used to redeem the notes at 101% of the aggregate principal amount plus accrued interest. Additionally, the release of prior guarantees under the 2013 Indenture alters the company's existing liability structure.
Outlook, Risks, and Contingencies
Management expects the New Notes offering to close prior to the consummation of the Omega Pharma acquisition. The filing includes standard forward-looking statements regarding the uncertainty of financial projections and the successful completion of the transaction. Key risks identified include product liability claims, market acceptance of products, changes in tax laws, and general pharmaceutical industry uncertainties. The company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the final terms and pricing of the three series of Senior Notes once the offering closes.
- Confirm the status and expected closing date of the Omega Pharma Invest NV acquisition.
- Review the preliminary prospectus supplement filed under Form S-3 for detailed debt covenants.
- Monitor the redemption clause conditions should the Omega Pharma acquisition fail to close.